Kazia Therapeutics (Kazia Therapeutics) Change In Receivables

: $2.31 Mil (TTM As of Jun. 2023)

View and export this data going back to 1999. Start your Free Trial

Kazia Therapeutics's change in receivables for the quarter that ended in Jun. 2023 was $2.75 Mil. It means Kazia Therapeutics's Accounts Receivable declined by $2.75 Mil from Dec. 2022 to Jun. 2023 .

Kazia Therapeutics's change in receivables for the fiscal year that ended in Jun. 2023 was $2.32 Mil. It means Kazia Therapeutics's Accounts Receivable declined by $2.32 Mil from Jun. 2022 to Jun. 2023 .

Kazia Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Kazia Therapeutics's liquidation value for the six months ended in Jun. 2023 was $-7.24 Mil.

Kazia Therapeutics Change In Receivables Historical Data

The historical data trend for Kazia Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

0.48

0.25

-3.84

-0.01

2.32

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables																-4.60	-1.18	1.15	-0.44	2.75

Kazia Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.31 Mil.

Kazia Therapeutics (NAS:KZIA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Kazia Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.001	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Kazia Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Kazia Therapeutics's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.517	-	10.761	+	0.75 * 0.001	+	0.5 * 0
=	-7.24

Kazia Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204